AA
NKTR icon

ALPS Advisors’s Nektar Therapeutics NKTR Stock Holding History

ALPS Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-705
Closed -$376K – 943
2019
Q2 		$376K Sell
705
-37
-5% -$18.6K ﹤0.01% 711
2019
Q1 		$374K Sell
742
-692
-48% -$410K ﹤0.01% 824
2018
Q4 		$707K Sell
1,434
-6
-0.4% -$3.62K 0.01% 389
2018
Q3 		$1.32M Buy
+1,440
New +$1.23M 0.01% 313
2018
Q2 		– Sell
-140
Closed -$223K – 957
2018
Q1 		$223K Buy
+140
New +$180K ﹤0.01% 829
2017
Q4 		– Sell
-10,264
Closed -$3.69M – 869
2017
Q3 		$3.69M Buy
10,264
+928
+10% +$290K 0.03% 156
2017
Q2 		$2.74M Buy
+9,336
New +$2.7M 0.02% 167

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ALPS Advisors's NKTR Position: Q3 2019 in Review

ALPS Advisors sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 705 shares — an estimated $376K sold.

ALPS Advisors first reported a position in NKTR in Q2 2017 and held it in 7 quarters. The position peaked at $3.69M in Q3 2017. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • ALPS Advisors reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • ALPS Advisors sold 705 Nektar Therapeutics shares in Q3 2019, an estimated $376K.
  • ALPS Advisors first reported a position in Nektar Therapeutics in Q2 2017 and held it in 7 quarters.
  • ALPS Advisors's Nektar Therapeutics position peaked at $3.69M in Q3 2017.
  • 287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on ALPS Advisors's 13F filing for Q3 2019, filed 4 Nov 2019.